Six-Month Survival After Extracorporeal Membrane Oxygenation for Severe COVID-19

Show full item record



Permalink

http://hdl.handle.net/10138/333352

Citation

Biancari , F , Mariscalco , G , Dalen , M , Settembre , N , Welp , H , Perrotti , A , Wiebe , K , Leo , E , Loforte , A , Chocron , S , Pacini , D , Juvonen , T , Broman , L M , Di Perna , D , Yusuff , H , Harvey , C , Mongardon , N , Maureira , J P , Levy , B , Falk , L , Ruggieri , V G , Zipfel , S , Folliguet , T & Fiore , A 2021 , ' Six-Month Survival After Extracorporeal Membrane Oxygenation for Severe COVID-19 ' , Journal of Cardiothoracic and Vascular Anesthesia , vol. 35 , no. 7 , pp. 1999-2006 . https://doi.org/10.1053/j.jvca.2021.01.027

Title: Six-Month Survival After Extracorporeal Membrane Oxygenation for Severe COVID-19
Author: Biancari, Fausto; Mariscalco, Giovanni; Dalen, Magnus; Settembre, Nicla; Welp, Henryk; Perrotti, Andrea; Wiebe, Karsten; Leo, Enrico; Loforte, Antonio; Chocron, Sidney; Pacini, Davide; Juvonen, Tatu; Broman, L. Mikael; Di Perna, Dario; Yusuff, Hakeem; Harvey, Chris; Mongardon, Nicolas; Maureira, Juan P.; Levy, Bruno; Falk, Lars; Ruggieri, Vito G.; Zipfel, Svante; Folliguet, Thierry; Fiore, Antonio
Contributor: University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
Date: 2021-07
Language: eng
Number of pages: 8
Belongs to series: Journal of Cardiothoracic and Vascular Anesthesia
ISSN: 1053-0770
URI: http://hdl.handle.net/10138/333352
Abstract: Objectives: The authors evaluated the outcome of adult patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) requiring the use of extracorporeal membrane oxygenation (ECMO). Design: Multicenter retrospective, observational study. Setting: Ten tertiary referral university and community hospitals. Participants: Patients with confirmed severe COVID-19-related ARDS. Interventions: Venovenous or venoarterial ECMO. Measurements and Main Results: One hundred thirty-two patients (mean age 51.1 +/- 9.7 years, female 17.4%) were treated with ECMO for confirmed severe COVID-19-related ARDS. Before ECMO, the mean Sequential Organ Failure Assessment score was 10.1 +/- 4.4, mean pH was 7.23 +/- 0.09, and mean PaO2/fraction of inspired oxygen ratio was 77 +/- 50 mmHg. Venovenous ECMO was adopted in 122 patients (92.4%) and venoarterial ECMO in ten patients (7.6%) (mean duration, 14.6 +/- 11.0 days). Sixty-three (47.7%) patients died on ECMO and 70 (53.0%) during the index hospitalization. Six-month all-cause mortality was 53.0%. Advanced age (per year, hazard ratio [HR] 1.026, 95% CI 1.000-1-052) and low arterial pH (per unit, HR 0.006, 95% CI 0.000-0.083) before ECMO were the only baseline variables associated with increased risk of six-month mortality. Conclusions: The present findings suggested that about half of adult patients with severe COVID-19 -related ARDS can be managed successfully with ECMO with sustained results at six months. Decreased arterial pH before ECMO was associated significantly with early mortality. Therefore, the authors hypothesized that initiation of ECMO therapy before severe metabolic derangements subset may improve survival rates significantly in these patients. These results should be viewed in the light of a strict patient selection policy and may not be replicated in patients with advanced age or multiple comorbidities. (C) 2021 The Authors. Published by Elsevier Inc.
Subject: extracorporeal membrane oxygenation
ECMO
ECLS
coronavirus disease 2019
COVID-19
acute respiratory distress syndrome
ARDS
RESPIRATORY-DISTRESS-SYNDROME
CORONAVIRUS DISEASE 2019
OUTCOMES
SUPPORT
COHORT
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
PIIS1053077021000628_1_.pdf 606.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record